250 related articles for article (PubMed ID: 2872225)
1. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs.
Lamberts SW; Zweens M; Verschoor L; del Pozo E
J Clin Endocrinol Metab; 1986 Jul; 63(1):16-9. PubMed ID: 2872225
[TBL] [Abstract][Full Text] [Related]
2. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine.
Chiodini PG; Cozzi R; Dallabonzana D; Oppizzi G; Verde G; Petroncini M; Liuzzi A; del Pozo E
J Clin Endocrinol Metab; 1987 Mar; 64(3):447-53. PubMed ID: 2880861
[TBL] [Abstract][Full Text] [Related]
3. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation.
Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A
J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007
[TBL] [Abstract][Full Text] [Related]
4. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acromegaly with the long-acting somatostatin analog SMS 201-995.
Barkan AL; Kelch RP; Hopwood NJ; Beitins IZ
J Clin Endocrinol Metab; 1988 Jan; 66(1):16-23. PubMed ID: 2891720
[TBL] [Abstract][Full Text] [Related]
6. The response of serum growth hormone levels to the long-acting somatostatin analog SMS 201-995 in acromegaly.
Comi RJ; Gorden P
J Clin Endocrinol Metab; 1987 Jan; 64(1):37-42. PubMed ID: 2878009
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
8. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients.
Lamberts SW; Oosterom R; Neufeld M; del Pozo E
J Clin Endocrinol Metab; 1985 Jun; 60(6):1161-5. PubMed ID: 2860119
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly.
Wagenaar AH; Harris AG; van der Lely AJ; Lamberts SW
Acta Endocrinol (Copenh); 1991 Dec; 125(6):637-42. PubMed ID: 1789059
[TBL] [Abstract][Full Text] [Related]
10. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients.
Lamberts SW; Verleun T; Hofland L; Del Pozo E
Clin Endocrinol (Oxf); 1987 Jul; 27(1):11-23. PubMed ID: 2888550
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin analog treatment of acromegaly: new aspects.
Lamberts SW; del Pozo E
Horm Res; 1988; 29(2-3):115-7. PubMed ID: 2900190
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects.
Halse J; Harris AG; Kvistborg A; Kjartansson O; Hanssen E; Smiseth O; Djøsland O; Hass G; Jervell J
J Clin Endocrinol Metab; 1990 May; 70(5):1254-61. PubMed ID: 2186055
[TBL] [Abstract][Full Text] [Related]
13. Treatment with octreotide and bromocriptine in patients with acromegaly: an open pharmacodynamic interaction study.
Fredstorp L; Kutz K; Werner S
Clin Endocrinol (Oxf); 1994 Jul; 41(1):103-8. PubMed ID: 8050122
[TBL] [Abstract][Full Text] [Related]
14. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly.
Lamberts SW; Zweens M; Klijn JG; van Vroonhoven CC; Stefanko SZ; Del Pozo E
Clin Endocrinol (Oxf); 1986 Aug; 25(2):201-12. PubMed ID: 2878748
[TBL] [Abstract][Full Text] [Related]
15. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly.
Timsit J; Chanson P; Larger E; Duet M; Mosse A; Guillausseau PJ; Harris AG; Moulonguet M; Warnet A; Lubetzki J
Acta Endocrinol (Copenh); 1987 Sep; 116(1):108-12. PubMed ID: 2889306
[TBL] [Abstract][Full Text] [Related]
16. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years.
Lamberts SW; Uitterlinden P; del Pozo E
J Clin Endocrinol Metab; 1987 Oct; 65(4):703-10. PubMed ID: 2888785
[TBL] [Abstract][Full Text] [Related]
17. Therapy of acromegaly with SMS 201-995: long-term studies.
Tolis G; Malachtari S; Mortoglou A; Rigas G; Saridakis C; Kamillaris T; Andreou J; Kimpouris Y; del Pozo E; Yotis A
Scand J Gastroenterol Suppl; 1986; 119():149-53. PubMed ID: 2876499
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness of 2-hourly versus 8-hourly subcutaneous injections of a somatostatin analog (SMS 201-995) in the treatment of acromegaly.
Wang C; Lam KS; Arceo E; Chan FL
J Clin Endocrinol Metab; 1989 Sep; 69(3):670-7. PubMed ID: 2668325
[TBL] [Abstract][Full Text] [Related]
19. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly.
Fløgstad AK; Halse J; Grass P; Abisch E; Djøseland O; Kutz K; Bodd E; Jervell J
J Clin Endocrinol Metab; 1994 Aug; 79(2):461-5. PubMed ID: 8045964
[TBL] [Abstract][Full Text] [Related]
20. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients.
Christensen SE; Weeke J; Orskov H; Møller N; Flyvbjerg A; Harris AG; Lund E; Jørgensen J
Clin Endocrinol (Oxf); 1987 Sep; 27(3):297-306. PubMed ID: 2892599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]